CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course
Abstract Objectives Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods To evaluate the potential clinical significance of CEA expression...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-06-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099404050006016 |
|---|---|
| author | Henning Plage Kira Furlano Jörg Neymeyer Sarah Weinberger Benedikt Gerdes Mandy Hubatsch Bernhard Ralla Antonia Franz Annika Fendler Michela deMartino Florian Roßner Simon Schallenberg Sefer Elezkurtaj Martina Kluth Maximilian Lennartz Niclas C. Blessin Andreas H. Marx Henrik Samtleben Margit Fisch Michael Rink Krystian Kaczmarek Thorsten Ecke Steffen Hallmann Stefan Koch Nico Adamini Sarah Minner Ronald Simon Guido Sauter Joachim Weischenfeldt Tobias Klatte Thorsten Schlomm David Horst Henrik Zecha Marcin Slojewski |
| author_facet | Henning Plage Kira Furlano Jörg Neymeyer Sarah Weinberger Benedikt Gerdes Mandy Hubatsch Bernhard Ralla Antonia Franz Annika Fendler Michela deMartino Florian Roßner Simon Schallenberg Sefer Elezkurtaj Martina Kluth Maximilian Lennartz Niclas C. Blessin Andreas H. Marx Henrik Samtleben Margit Fisch Michael Rink Krystian Kaczmarek Thorsten Ecke Steffen Hallmann Stefan Koch Nico Adamini Sarah Minner Ronald Simon Guido Sauter Joachim Weischenfeldt Tobias Klatte Thorsten Schlomm David Horst Henrik Zecha Marcin Slojewski |
| author_sort | Henning Plage |
| collection | DOAJ |
| description | Abstract Objectives Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format. Results CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5.8%) with moderate, and 192 (7.9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low‐grade, 32.0% of 178 pTaG2 high‐grade, and 43.0% of 93 pTaG3 tumours (p < 0.0001). In 1335 pT2–4 carcinomas, CEA positivity (34.1%) was lower than in pTaG3 tumours. Within pT2–4 carcinomas, CEA staining was unrelated to pT, pN, grade, L‐status, V‐status, overall survival, recurrence free survival, and cancer specific survival (p > 0.25). Conclusion CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2–4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2–4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti‐CEA drugs. |
| format | Article |
| id | doaj-art-81a61db9b6264355b1ed85e97fb6d1fe |
| institution | DOAJ |
| issn | 2688-4526 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-81a61db9b6264355b1ed85e97fb6d1fe2025-08-20T02:40:30ZengWileyBJUI Compass2688-45262024-06-015669970610.1002/bco2.354CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease courseHenning Plage0Kira Furlano1Jörg Neymeyer2Sarah Weinberger3Benedikt Gerdes4Mandy Hubatsch5Bernhard Ralla6Antonia Franz7Annika Fendler8Michela deMartino9Florian Roßner10Simon Schallenberg11Sefer Elezkurtaj12Martina Kluth13Maximilian Lennartz14Niclas C. Blessin15Andreas H. Marx16Henrik Samtleben17Margit Fisch18Michael Rink19Krystian Kaczmarek20Thorsten Ecke21Steffen Hallmann22Stefan Koch23Nico Adamini24Sarah Minner25Ronald Simon26Guido Sauter27Joachim Weischenfeldt28Tobias Klatte29Thorsten Schlomm30David Horst31Henrik Zecha32Marcin Slojewski33Department of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyInstitute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyInstitute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyInstitute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyInstitute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg GermanyInstitute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg GermanyInstitute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg GermanyDepartment of Pathology Academic Hospital Fuerth Fuerth GermanyDepartment of Pathology Academic Hospital Fuerth Fuerth GermanyDepartment of Urology University Medical Center Hamburg‐Eppendorf Hamburg GermanyDepartment of Urology Marienhospital Hamburg Hamburg GermanyDepartment of Urology and Urological Oncology Pomeranian Medical University Szczecin PolandDepartment of Urology Helios Hospital Bad Saarow Bad Saarow GermanyDepartment of Urology Helios Hospital Bad Saarow Bad Saarow GermanyDepartment of Pathology Helios Hospital Bad Saarow Bad Saarow GermanyDepartment of Urology Albertinen Hospital Hamburg GermanyInstitute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg GermanyInstitute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg GermanyInstitute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Helios Hospital Bad Saarow Bad Saarow GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyInstitute of Pathology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin GermanyDepartment of Urology and Urological Oncology Pomeranian Medical University Szczecin PolandAbstract Objectives Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format. Results CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5.8%) with moderate, and 192 (7.9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low‐grade, 32.0% of 178 pTaG2 high‐grade, and 43.0% of 93 pTaG3 tumours (p < 0.0001). In 1335 pT2–4 carcinomas, CEA positivity (34.1%) was lower than in pTaG3 tumours. Within pT2–4 carcinomas, CEA staining was unrelated to pT, pN, grade, L‐status, V‐status, overall survival, recurrence free survival, and cancer specific survival (p > 0.25). Conclusion CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2–4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2–4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti‐CEA drugs.https://doi.org/10.1002/bco2.354bladder cancerCEACEACAM5immunohistochemistryprognosistissue microarray |
| spellingShingle | Henning Plage Kira Furlano Jörg Neymeyer Sarah Weinberger Benedikt Gerdes Mandy Hubatsch Bernhard Ralla Antonia Franz Annika Fendler Michela deMartino Florian Roßner Simon Schallenberg Sefer Elezkurtaj Martina Kluth Maximilian Lennartz Niclas C. Blessin Andreas H. Marx Henrik Samtleben Margit Fisch Michael Rink Krystian Kaczmarek Thorsten Ecke Steffen Hallmann Stefan Koch Nico Adamini Sarah Minner Ronald Simon Guido Sauter Joachim Weischenfeldt Tobias Klatte Thorsten Schlomm David Horst Henrik Zecha Marcin Slojewski CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course BJUI Compass bladder cancer CEA CEACAM5 immunohistochemistry prognosis tissue microarray |
| title | CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course |
| title_full | CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course |
| title_fullStr | CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course |
| title_full_unstemmed | CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course |
| title_short | CEA (CEACAM5) expression is common in muscle‐invasive urothelial carcinoma of the bladder but unrelated to the disease course |
| title_sort | cea ceacam5 expression is common in muscle invasive urothelial carcinoma of the bladder but unrelated to the disease course |
| topic | bladder cancer CEA CEACAM5 immunohistochemistry prognosis tissue microarray |
| url | https://doi.org/10.1002/bco2.354 |
| work_keys_str_mv | AT henningplage ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT kirafurlano ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT jorgneymeyer ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT sarahweinberger ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT benediktgerdes ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT mandyhubatsch ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT bernhardralla ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT antoniafranz ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT annikafendler ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT michelademartino ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT florianroßner ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT simonschallenberg ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT seferelezkurtaj ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT martinakluth ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT maximilianlennartz ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT niclascblessin ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT andreashmarx ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT henriksamtleben ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT margitfisch ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT michaelrink ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT krystiankaczmarek ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT thorstenecke ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT steffenhallmann ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT stefankoch ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT nicoadamini ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT sarahminner ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT ronaldsimon ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT guidosauter ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT joachimweischenfeldt ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT tobiasklatte ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT thorstenschlomm ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT davidhorst ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT henrikzecha ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse AT marcinslojewski ceaceacam5expressioniscommoninmuscleinvasiveurothelialcarcinomaofthebladderbutunrelatedtothediseasecourse |